Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital | China

Author Profile

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
- Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
- He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
- Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
- RMB 300,000 (January 2023 – December 2025)
Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
- RMB 600,000 (January 2023 – December 2025)
Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
- RMB 200,000 (January 2024 – December 2026)
Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
- RMB 140,000 (January 2024 – December 2024)
Medical School of Peking University, Young Scientists Innovation Fund 🌟
- RMB 40,000
Internal Fund of Peking University Cancer Hospital 🌟
- RMB 80,000
Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
- RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

📊🔬Notable Publication:

A Highly Specific Multiple Enhancement Theranostic Nanoprobe for PET/MRI/PAI Image-Guided Radioisotope Combined Photothermal Therapy in Prostate Cancer
- Authors: Xia, L., Meng, X., Wen, L., … Yang, Z., Zhu, H.
- Journal: Small
- Year: 2021

Noninvasive Evaluation of PD-L1 Expression Using Copper 64 Labeled Peptide WL12 by Micro-PET Imaging in Chinese Hamster Ovary Cell Tumor Model
- Authors: Jiang, J., Li, D., Liu, T., … Yang, Z., Zhu, H.
- Journal: Bioorganic and Medicinal Chemistry Letters
- Year: 2021

First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
- Authors: Duan, X., Xia, L., Zhang, Z., … Sheng, X., Yang, X.
- Journal: Clinical Cancer Research
- Year: 2023

64Cu-PSMA-BCH: A New Radiotracer for Delayed PET Imaging of Prostate Cancer
- Authors: Liu, T., Liu, C., Zhang, Z., … Zhu, H., Yang, Z.
- Journal: European Journal of Nuclear Medicine and Molecular Imaging
- Year: 2021

Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
- Authors: Wen, L., Xia, L., Guo, X., … Yang, Z., Zhu, H.
- Journal: Frontiers in Oncology
- Year: 2021

EARLY ACADEMIC PURSUITS

Rommel Mario Rodríguez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of Pará in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of Ribeirão Preto, University of São Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of São Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of Pará.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario Rodríguez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in Belém, Pará, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.